Relay Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Relay Therapeutics, Inc. - overview
Established
2016
Location
Cambridge, MA-Massachusetts, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2016 by David E. Shaw, Dorothee Kern, Mark Murcko, and Matthew Jacobson, Relay Therapeutics, Inc. provides an allosteric drug-discovery platform that intends to apply computational techniques to protein motion. In 2018, Relay Therapeutics, Inc.
raised USD 400 million in a Series C funding, led by SB Investment Advisers, with participation from Foresite Capital, Perceptive Advisors, Tavistock Group, Alexandria Venture Investments, BVF Partners, Casdin Capital, EcoR1 Capital, and GV. In July 2020, Relay Therapeutics, Inc. raised USD 400 million in an IPO, selling 20 million shares at USD 20 per share. The company is listed on Nasdaq under the ticker symbol RLAY.
As of October 2021, Sanjiv K. Patel is the CEO and President of Relay Therapeutics, Inc. and employs approximately 232 people. Relay Therapeutics, Inc.
provides Relay Therapeutics’ Dynamo™ platform that integrates leading computation and experimental approaches to target drug-protein that have previously been intractable. The company develops oncology therapeutics through an allosteric drug-discovery platform. It works to improve small molecule therapeutic discovery in targeted cancer, with an initial focus on improving the drug discovery process. The platform uses computational methods and experimental approaches to discover proteins' motion and function inside human cells to treat patients with cancer.
Its products include RLY-1971, RLY-4008, and RLY-PI3K1047, a compound that targets cancer-associated mutant variants. The company generated total revenue of USD 246. 2 million for the first three quarters of 2021. In the fiscal year 2020, the company generated USD 82.
654 million in revenue.
Current Investors
Third Rock Ventures, Alexandria Venture Investments, GV
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.relaytx.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Relay Therapeutics, Inc. - timeline of key events
Relay Therapeutics, Inc. - financials
| Fiscal Year Ended | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | 82,654,000 | 3,029,000 | 1,381,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | (96.3%) | (54.4%) | - | - | - |
| EBITDA (USD) | (45,500,000) | (81,300,000) | (52,663,000) | (358,721,000) | (293,963,000) | - | - | - |
| Operating Income (USD) | (47,700,000) | (84,100,000) | (55,796,000) | (364,698,000) | (299,275,000) | - | - | - |
| Operating Margin | - | - | (67.5%) | (12040.2%) | (21670.9%) | - | - | - |
| % EBITDA Margin | - | - | (63.7%) | (11842.9%) | (21286.2%) | - | - | - |
| NET Income (USD) | (48,800,000) | (75,300,000) | (52,412,000) | (363,872,000) | (290,509,000) | - | - | - |
| % Net Margin | - | - | (63.4%) | (12012.9%) | (21036.1%) | - | - | - |
Relay Therapeutics, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Relay Therapeutics, Inc. | - | ||||||||
| Private Placement/Follow on | Completed | Relay Therapeutics, Inc. | - | ||||||||
| Private Placement/Follow on | Completed | Relay Therapeutics, Inc. | - | ||||||||
| Add-on, Trade Sale | Completed | Zebi AI Therapeutics, Inc. | - | ||||||||
| IPO | Completed | Relay Therapeutics, Inc. | - |
Displaying 1 - 5 of 8
Relay Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.